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MP-MUSThe lastmajor advance in the treatment of glioblastomamultiforme (GBM)was the introduction of temozolomide
in 1999. Treatment with temozolomide following surgical debulking extends survival rate compared to radio-
therapy and debulking alone. However, virtually all glioblastoma patients experience disease progressionwithin
7 to 10 months. Although many salvage treatments, including bevacizumab, rechallenge with temozolomide,
and other alkylating agents, have been evaluated, none of these clearly improves survival. Monoamine oxidase
B (MAOB) is highly expressed in glioblastoma cell mitochondria, and mitochondrial function is intimately tied
to treatment-resistant glioblastoma progression. These glioblastoma properties provide a strong rationale for
pursuing a MAOB-selective pro-drug treatment approach that, upon drug activation, targets glioblastoma
mitochondria, especially mitochondrial DNA. MP-MUS is the lead compound in a family of pro-drugs designed
to treat GBM that is converted into the mature, mitochondria-targeting drug, P+-MUS, by MAOB. We show
that MP-MUS can successfully kill primary gliomas in vitro and in vivomouse xenograft models.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glioblastomamultiforme (GBM) is themost common and aggressive
malignant primary brain tumor in humans, accounting for one-ﬁfth of all
intracranial tumors (Stupp et al., 2005). The most effective therapies for
GBM are surgical resection (debulking), chemoradiation, and anti-
angiogenic agents (Omuro and DeAngelis, 2013). However, despite the
availability of these treatments, prognosis remains dismal with a mean
survival of approximately 15 months (Henriksson et al., 2011). The
search for more effective treatment regimens has beenmet with limited
success during the past 50 years. In the present study, we describe a che-
motherapeutic agent, MP-MUS, which speciﬁcally targets glioblastoma
mitochondria, andwedemonstrate its efﬁcacy in cultured humanprima-
ry GBM cells.
Mitochondria have three cellular functions: providing energy via ox-
idative phosphorylation, synthesizing cellular components (e.g., heme,
cardiolipin, and pyrimidine), and regulating apoptosis. The metabolic
function of mitochondria in cancer cells differs from that of healthy
cells (Warburg, 1956). Otto Warburg noted that, in contrast to normal
cells, which derive energy through the oxidative breakdown of pyru-
vate, cancer cells produce energy primarily through the anaerobic.A. Sharpe),
. This is an open access article underbreakdown of glucose. Although Warburg mistakenly thought that
this metabolic shift caused cancer, he correctly concluded that ATP
synthesis in the absence of mitochondrial respiration was an inefﬁcient
use of energy resources (Moreno-Sánchez et al., 2014). Nonetheless, can-
cer cells remain dependent on mitochondria for survival because mito-
chondrial dihydroorotate dehydrogenase is required for pyrimidine
synthesis (Lu et al., 2014). Based on their critical cellular functions,
mitochondria are attractive anti-cancer drug targets (Ubah and
Wallace, 2014).
Targeting mitochondria is also appealing due to the limited DNA re-
pair mechanisms in these organelles (Alexeyev, 2009). Mitochondria re-
pair damaged DNA through a simple base-excision repair mechanism.
However, this repair mechanism is not active in cells containing
damaged mitochondrial DNA (mtDNA), which effectively reduces the
development of chemoresistance in these cells (Stupp et al., 2005).
Thus, selective targeting of the mitochondrial genome is an attractive
anti-cancer strategy;mitochondriamay be the “Achilles' heel” of actively
proliferating cancer cells, including stem cells (Loureiro et al., 2013).
Glioblastoma mitochondria may be required for the maintenance and
function of invasive pseudopodia (Arismendi-Morillo et al., 2012),
which mediate the inﬁltration of cancer cells into the brain. Thus, a che-
motherapeutic agent that targets glioblastoma mitochondria may block
disease progression.
Monoamine oxidase type B (MAOB) is localized on the inner-face of
the outer mitochondrial membrane. MAOB is mainly expressed in glialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.MPTP/MPMUSbioactivation pathways. (A) Conversion ofMPTP (I) toMPP+ (III) via
MPDP+ (II) by sequential oxidation (‘O’); oxidation of MPTP is viaMAOB and oxidation of
MPDP+ is typically via the mitochondrial quinone pool. (B) Analogous conversion by
MAOB of MP-MUS (IV) to MD+-MUS (V). Again the dihydro species is converted to the
pyridium, P+-MUS (VI). One of the chloroethyl groups of the mustard can ionize to give
rise to either a 3-membered aziridinium (VII) or a 5-membered dihydrooxazolium (VIII)
reactive ring system.
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roactive amines, such as dopamine (Wang and Edmondson, 2011).
MAOB activity levels have been reported to be signiﬁcantly higher in
GBMs, low-grade astrocytomas, and anaplastic astrocytomas compared
to those of postmortem control brain (p b 0.01) (Gabilondo et al., 2008)
(Callado et al., 2011). Glioma cells have 5–10 times fewer mitochondria
than those of normal human astrocytes (Wolf et al., 2011) and far less
complex I–IV (Kiebish et al., 2009). Mitochondrial cytochrome oxidase
protein levels are ﬁve-fold lower in gliomas compared to those of nor-
mal brain tissue obtained from epileptic patients (Griguer et al., 2013).
In addition, the state-3 respiration rates of glioblastoma mitochondria
are 10-fold lower than those in normal human astrocytic mitochondria
(Oliva et al., 2011). However, the MAOB levels per cell are higher in gli-
omas compared to those of normal astrocytes and so levels ofMAOB per
mitochondria are higher in glioma than in astrocytes and other cells of
the brain.
The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) crosses the blood–brain barrier and is bioactivated by MAOB
oxidation (‘O’) to produce 1-methyl-4-phenyl-2,3-dihydropyridinium
(MPDP+). MPDP+ is further oxidized (‘O’) by coenzyme Q to 1-
methyl-4-phenylpyridinium (MPP+) (Shi et al., 1999) [summarized in
Fig. 1A (I–III)]. The conversion and neuronal toxicity of MPTP, which
causes symptoms similar to those associated with Parkinson's Disease,
can be blocked by MAOB inhibitors, such as selegiline (Visanji and
Brotchie, 2001).
Our strategy for the design of a glioblastoma chemotherapeutic
agent takes advantage of the high concentration of MAOB in gliomas
by synthesizing and testing the pro-drug substrate, MP-MUS,
which has a higher speciﬁcity for MAOB than MAO-A, and like the
MPTP/MPP+ pair generates a lipophilic cation (Fig. 1B). MP-MUS
is a chimeric MPTP-nitrogen mustard that accumulates in mito-
chondria through the MAOB-dependent mechanism of MPTP/
MPDP+/MPP+. Mitochondrial accumulation allows the alkylating
agent MP-MUS to target mtDNA and mitochondrial complexes. The
MP-MUS pro-drug, MP-MUS (IV), is oxidized by MAOB to form the in-
termediate MD-MUS+ (V), which is then oxidized by quinones to the
mature drug, P+-MUS (VI). The mitochondrial membrane potentials
(ΔΨ) of cancer cells are typically≈ 180 mV. Thus, the lipophilic cation
P+-MUS will accumulate in the mitochondrial matrix and reach con-
centrations that are approximately three orders of magnitude greater
than those in the cytosol, as with similar lipophilic cations (Reily et al.,
2013; Pathak et al., 2014; Rin Jean et al., 2014). Nitrogen mustards
alkylate DNA through a highly reactive, three-membered aziridinium
ring (VII). Based on this alkylating function, nitrogen mustards have
been used as chemotherapeutic agents since 1943 (DeVita and Chu,
2008) (Polavarapu et al., 2012). In addition to generating alkylating
aziridinium groups, the presence of an amide in MP-MUS/P+-MUS
allows the formation of dihydrooxazolium (VIII) alkylating agents.
P+-MUS accumulates in the mitochondrial matrix and alkylates
mtDNA and mitochondrial complexes, resulting in mitochondrial
dysfunction and cell death. Based on the high levels of MAOB in the
mitochondria of glioma cells, MP-MUS is expected to have increased
speciﬁcity for glioblastoma cells.We have recently shown thatMP-MUS
is a MAOB speciﬁc substrate and that the oxidized product, P+-MUS, is
indeed toxic toward cultured glioblastoma cells, but not normal human
astrocytes (Sharpe et al., 2015).
A possible disadvantage of our MAOB-catalyzed MP-MUS/P+-MUS
approach is that P+-MUS may cause similar effects as MPTP/MPP+,
potentially leading to Parkinson's disease. The dopaminergic neuronal
toxicity of MPTP results from efﬁcient uptake of astrocytic MPP+ gener-
ated by MAOB by the dopamine transporter. Other dopamine mimetics
that serve as dopamine transporter substrates include the closely related
4-(4-dimethylamino)phenyl-1-methylpyridinium (APP+) (Karpowicz
et al., 2013) and N,N′-dimethyl-4,4′-bipyridiniumdichloride or paraquat
(Rappold et al., 2011). The crystal structure of the Drosophila
melanogaster dopamine transporter in the nortriptyline-inhibited form,4M48 (Penmatsa et al., 2013), provides hints regarding the possible
actions of MPP+, APP+, and paraquat as dopamine mimetics. The
substrate-binding pocket is highly constrained. The substrates dopa-
mine, MPP+, APP+, and paraquat ﬁt into this pocket; however, the
parasol-like pair of phenyl rings in the inhibitor nortriptyline blocks
movement. In silico modeling indicated that P+-MUS will be a very
poor substrate of the dopamine transporter (Fig. S1).
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2.1. Primary Human GBM
Glioma cells were isolated within 10 min of tumor excision. Tumors
were homogenized with a pipette, and cells were grown for two weeks
in DMEM with 20% fetal bovine serum, GlutaMax-I, sodium pyruvate,
and penicillin/streptomycin. Unless otherwise speciﬁed, the same
growth medium was used in the following experiments. Glioma cells
were grown to conﬂuence 24 h after treatment with an identical
volume of drug (in DMSO) or DMSO alone (maximum 0.04% v/v of
DMSO/medium); cells were cultured in either Costar 96-well plates
(Corning, NYC, NY, USA) or 16-well Lab-Tek slide chambers (NalgeFig. 2. Effect of MP-MUS on mitochondrial membrane potential, mtDNA, and MAOB.
(A) Glioma incubated ± MP-MUS and ± selegiline for 24 h show mitochondrial damage
and upregulation of MAOB only when uninhibited MAOB is incubated with MP-MUS.
MP-MUS/MAOB induces a drop in ΔΨ, an increase in fpg-sensitive mtDNA lesions, and
an elevation ofMAOB levels. (B) Effects of MP-MUSwith respect to time; the ﬁrst changes
in mitochondrial function, ΔΨ, and damage are observed after 30min and continue up to
24 h. (C) The data presented in A and B is shown as a plot. All changes reported are at
p b 0.05, except fpg-sensitive DNA lesions at 2 h (‡), mean ± SEM, n= 8.
Fig. 3. LD50 of MP-MUS in primary human glioma. (A) Changes in live cell numbers and
%dead cells following 24 hour incubation with increasing concentrations ofMP-MUS indi-
cate an LD50 of≈80 μMMP-MUS. Mean ± SEM, n= 4 individual wells. (B) LDH and XTT
formazan assays performed on other half of the 96-well plate appear to demonstrate an
increase in levels of both XTT reduction and LDH, per living cell. Mean± SEM, n=8 indi-
vidual wells.Nunc, Rochester, NY, USA). After treatment, cells were grown for 24 h
in the absence or presence of all effectors (total volume of 250 μL).
The human glioma primary culture, BT150, was used at a low
passage number in all of the in vitro experiments presented in Figs. 2,
3, and 4 and Supplementary Figs. 2 and 3.
2.2. Fixation and Permeabilization
Cells in 96-well plates and 16-well slide tanks were ﬁxed in ice-cold
4% paraformaldehyde for at least one hour and then washed in
phosphate-buffered saline solution (PBS) (Thermo Fisher Scientiﬁc,
Rockford, IL, USA). MitoTracker™, MitoSox™ Red, H2-DCF, and Hoe
assays were performed in non-permeabilized cells. Hydroxyl radical,
aldehyde & ketone, antibody labeling, ddTUNEL, Fpg-ddTUNEL, and
blunt-ended ligation experiments were performed with cells that were
permeabilized with 0.1% Triton X-100 in PBS (Thermo Fisher Scientiﬁc,
Rockford, IL, USA).
2.3. Probes
Mitochondrial membrane potential was assayed with the
MitoTracker™ (MT, M22425) probe. Mitochondrial superoxide genera-
tion required the MitoSox Red (M36008) probe. Probes or dyes used for
Fig. 4. MP-MUS induces ROS and causes LDHA and mitochondrial upregulation.
(A) Increase in oxidative stress; representative images of glioma labeled for hydrazine re-
active aldehydes/ketones (I), ddTUNEL (II), peroxides (III) hydroxyl radical (IV) all labeled
green, with MAOB labeled red. The ﬁnal panel shows the levels of LDHA (V). The arrows
point to cells with massive oxidative stress. (B) MP-MUS increases levels of oxidative
stress, DNA breaks, mitochondrial enzymes, and LDHA. (C) 3′OH DNA lesions caused by
MP-MUS are colocalized with mitochondrial MAOB, and are exclusively cytosolic and
non-nuclear.
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H36004) for hydroxyl radicals, 2′,7′-dichlorodihydroﬂuorescein diacetate
(H2-DCFDA/H2-DCF, D399) for peroxides, N-(aminooxyacetyl)-N′-(D-
Biotinoyl) hydrazine (ARP, A10550) for aldehydes & ketones, either
Hoechst 33342 (Hoe, H21492) or 4′,6-Diamidino-2-Phenylindole (DAPI,
D3571) for DNA, either FITC-Avidin (A2662) or Texas Red-Avidin
(A2665) for biotinylated probes, goat anti-mouse IgG antibody labeled
with Alexa Fluor®594 (A11032) or Alexa Fluor®488 (A10680) for prima-
ry mouse antibodies, and Alexa Fluor®594 (A11012) or Alexa Fluor®488
(A11034) for goat anti-rabbit IgG antibody. All reagents were purchased
from Invitrogen/Molecular Probes, Eugene, Oregon, USA.
2.3.1. ddTUNEL
A reaction buffer for terminal deoxynucleotidyl transferase (Tdt)
was prepared by diluting a stock solution of TUNEL buffer (125 mM
Tris–HCl, 1 M sodium cacodylate, 1.25 mg/mL BSA, pH 6.6) at a 1:5
ratio and a 25 mM cobalt chloride stock solution at a 1:25 ratio. Each
well was washed twice with 0.1% Triton X-100 in PBS and then twice
in reaction buffer. Cells were then incubated for one hour in 50 μL of
the reaction buffer containing 20 units/mL of Tdt and 250 nM of
Biotin-16-ddUTP (Roche, IN, USA) (Baskin et al., 2010b).
2.3.2. Fpg-ddTUNEL Assay
Permeabilized cells were washed, incubated with NEBuffer 3 for
30 min, and then treated with 50 μL of the same buffer containing 100
units/mL of calf intestinal alkaline phosphatases (CAIP, Sigma) for ≥2 hto convert 3′PO4 to 3′OH ends. Cells were washed twice with Tdt reac-
tion buffer before capping the 3′OH ends with biotinylated-ddUTP,
blocking with avidin and biotin. Samples were washed twice in
10mMHEPES, 10mMNaCl, 2mMEDTA, and 0.1% BSA. The same buffer
(50 μL) containing 100 units/mL of formamidopyrimidine DNA
glycosylase (Fpg) (USB, Cleveland, OH, USA) was added to each well,
and cells were incubated in a humidiﬁed chamber for ≥2 h. Each sample
waswashed twice in 1× PBS in NEBuffer 3, and 50 μL of the same buffer
containing 100 units/mL of CIAPwas applied to each section before in-
cubating for ≥2 h. Samples were treated for ddTUNEL labeling (Baskin
et al., 2010b).
2.3.3. Blunt-ended DNA Breaks
A blunt-ended oligonucleotide probe (biotinylated, hairpin-
structured) was used as previously described (Baskin et al., 2010a).
The wells were pre-incubated with ligation buffer without probe
(66 mM Tris HCl, pH 7.5, 5 mM MgCl2, 0.1 mM dithioerythritol, 1 mM
ATP, and 15% polyethylene glycol-8000) and then aspirated. The liga-
tion mix containing probe (35 μg/μL) and T4 DNA ligase (0.5 U/μL)
(New England Biolabs, Ipswich, MA, USA) was added prior to an
overnight incubation in a humidiﬁed chamber. The biotinylated probes
were visualized using either FITC-Avidin or Texas Red-Avidin.
2.3.4. Epiﬂuorescence Microscopy
Signals were acquired with the Nikon Eclipse TE2000-E ﬂuorescence
microscope. The microscope was equipped with a CoolSnap ES digital
camera system (RoperScientiﬁc) containing a CCD-1300-Y/HS 1392 ×
1040 imaging array cooled by Peltier. Imageswere recorded and analyzed
using Nikon NIS-Elements software.
2.3.5. Transmission Microscopy
Images were acquired using the Olympus IX71 microscope, which
was equipped with an Olympus DP72 camera and Olympus TH4-100
light source. Images were recorded using the DP2-BSW software
(Olympus).
2.4. Assay for XTT, LDH, and Cell Viability
We grew glioma cells in 96-well plates and 16-well Lab-Tek slide
chambers (total volume of 240 μL). At t = 0, 10 μL DMSO was added
with or without effectors (titrated along plate columns) and accompa-
nied by equivalent concentrations of MP-MUS. At t = 23 h, columns
9–12 were incubated with Hoechst 33342 (ﬁnal concentration of
10 μM), and columns 1–8 were washed with XTT buffer (3 mM
Tris–HCl, 30 mM HEPES, 10 mM NaCl, pH 7.4, 37 °C).
2.4.1. XTT Assay
A solution of 1.5 mM 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide (XTT, Invitrogen) and 10 μM phena-
zine methosulfate (PMS, Sigma) XTT buffer (Roehm et al., 1991) was
freshly prepared and placed in a pre-warmed BioTek Synergy HT plate
reader. The ﬁrst 64 wells were read at 575–675 nm every two and
a half minutes. After formazan generation became non-linear
(N10 min), the XTT/PMS was removed, wells were washed twice, and
the ﬁrst 64 wells were used for LDH measurement. XTT generation
rate was calculated from the 575–675-nm reading taken at 10 min
minus the reading taken at 2.5 min.
2.4.2. LDH Assay
A 100 μL solution [110 mM lactate, 3.35 mM NAD+, 350 μM
resazurin, and 2.2 units/mL of diaphorase in 3 mM Tris, 30 mM HEPES,
10 mM NaCl buffer, and 0.45% Triton X-100], pH 7.4, 37 °C (Sharpe
et al., 2012) was added to each well. The resoruﬁn that eventually
formed was measured over 20 min in a plate reader using 530/25 nm
excitation and 590/35 nm emission. The rate of resoruﬁn formation
was calculated over the 20-minute period when the curve was linear.
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freshplate (n=16 readings from individualwells). LDH levelswere cal-
culated from t= 20 min minus t= 5min, subtracting the background
readings recorded during the same time period.
2.4.3. Cell Counts
At t=24 h and after two-thirds of the plate had been used for XTT/
LDH assays, the remaining cells were ﬁxed with ice-cold paraformalde-
hyde (PFA). We counted cells in the center ﬁeld at 20× magniﬁcation.
There was an average of 150 cells per image when cells were conﬂuent
and between 1 and 8 dead/dying cells in the sameﬁeld. Dead/dying cells
were identiﬁed by condensed nuclei with signal intensities greater than
three times those of the median cell nuclei. Dividing cells were identi-
ﬁed by paired and brightly labeled nuclei and were counted as two
living cells.
2.4.4. Labeling Glioma in 16-well Slide Tanks
At t= 23.5 h, cells were incubated with 10 μMHoe and either 1 μM
MitoTracker™, 10 μMMitosox, 10 μMH2-DCFAM, 10 μMHPF, or DMSO
for 30min prior to ﬁxing in ice-cold PFA. Afterwashing in PBS, the levels
of ﬂuorophore emission from the ﬁxed cells were measured. Cells were
subsequently permeabilized and labeled with probes or antibodies for
DNA lesions.
2.4.5. Primary Antibodies
Antibodies included rabbit anti-MAOB (clone EPR7103,
Cat#ab125010, Abcam), Armenian Hamster monoclonal Anti-CD3
epsilon antibody (clone 145-2C11, Cat#ab24947, Abcam), mouse anti-
cytochrome c (clone 7H8, Cat#sc-13560, Santa Cruz Biotechnology,
CA), mouse anti-vimentin antibody clone V9 (M0725, Dako, North
America, Carpinteria, CA), mouse anti-LDHA (E-9 clone, Cat#sc-
137243, Santa Cruz Biotechnology) andmousemonoclonal tyrosine hy-
droxylase (F-11 clone, Cat#sc−25269). Dako antibody diluent (S3022)
and protein blocking solution (X0909) were used.
2.5. Animal Models of Primary Brain Glioma
2.5.1. Study Approval
The animal research inmicewas conducted according to Institution-
al Animal Care and Use Committee (IACUC) Protocol AUP-0315-0016,
approved by the IACUC of Methodist Hospital. All animal care proce-
dures conformed to the Guide for the Care and Use of Laboratory
Animals (National Research Council, National Academy Press,
Washington DC 1996, USA). Gliomal cells used in laboratory studies
do not meet the deﬁnition of human subject research per 45 CFR
46.102 since cells were isolated from deidentiﬁed patient tissues and
have no identiﬁable private information.Initial toxicology model. 10
nude mice (NU-FoxnNu) were injected into the tail vein with 200 μL sa-
line or 0.2 mg MP-MUS (in saline) on days 0, 12, and 23. The following
day they were sacriﬁced and their major organs were ﬁxed. After ﬁxa-
tion, immunohistochemical slides of 10 μM thickness were prepared.
Laterally sliced brain sections of all ten animals were investigated for
the levels and the localization of tyrosine hydroxylase; the gold stan-
dard marker for the identiﬁcation of dopaminergic neurons, which is
the rate limiting enzyme in dopamine synthesis. A mouse monoclonal
antibody (F-11, Santa Cruz, sc-25269) was used to identify dopaminer-
gic neurons and nuclei were counter stained with hematoxylin.
2.5.2. Flank Model
Glioblastoma cell line BT111 was derived from a high-grade GBM.
BT111 contains an unmethylated MGMT promoter region and lacks
the EGFR oncogene (i.e., no demonstrable gene ampliﬁcation). In the
ﬂank model of GBM using BT11, 20 nude mice (NU-FoxnNu) were
injected with 1 × 106 primary human glioblastoma cells at the 6th
passage in media:Matrigel (1:1). Animals were monitored for changes
in weight and tumor volume based on caliper measurements. Thegreatest longitudinal diameter (length) and greatest transverse
diameter (width) were recorded. Volume was calculated by the modi-
ﬁed ellipsoidal formula (Euhus et al., 1986) as tumor volume = 1/
2(length × width2). Mice with an average tumor volume of 45 mm3
after four weeks were categorized into two groups of seven. Either sa-
line or 0.2 mg MP-MUS (in saline) was injected into the tail vein on
days 0, 12, and 23; mice weremonitored until day 36 (the last injection
time point). At this time, two of the control animals and all of the MP-
MUS-treated animals were sacriﬁced. Tumors were excised, halved,
and either preserved in PFA or grown in cell culture media. Tumor
volumes (87 mm3) were determined for the remaining ﬁve control
animals. Each of these mice was given one tail-vein injection of 0.2 mg
MP-MUS in saline, and tumor volume was re-assessed 24 h later.
2.5.3. Brain Model
Recently, Iwami and co-workers (Iwami et al., 2012) developed an
innovative methodology for injecting human GBM cultures into
mouse brain via the postglenoid foramen. Percutaneous injection into
the adult mouse brain via the postglenoid foramen is technically
simpler, more time efﬁcient, and less stressful for mice than traditional
stereotaxic methodologies. GBM cells (5 × 104) in a solution of
Matrigel™media (4:6) were injected into the postglenoid foramen of
40 SCID mice. The primary GBM culture BT116 was from an aggressive,
grade IVGBM thatwas fatal in less than two years. An excessive number
of SCID mice died following the glioma injections due to brain hemor-
rhage; this complication or high death rate was not observed with
NU-FoxnNu or NIHIII mice using the same brain injection methodology
(data not shown). After more than three months, 24 animals were
asymptomatic. Two animals were sacriﬁced on day 115; brains were
ﬁxed/embedded in wax and archived as pre-treatment controls. The re-
maining 22 animals were split into MP-MUS-treated and saline-treated
groups. The animals received tail-vein injections of saline or 0.2mgMP-
MUS in saline on days 115, 123, and 131 and monitored until day 307,
which was the end of the study. When mice became symptomatic,
theywere sacriﬁced, and their brainswere removed andﬁxed in 2%PFA.
2.6. Histological Analysis of GBM in Mouse Brain
To detect human glioblastoma cells in mouse brain, we used a 1:100
dilution of the mouse anti-vimentin antibody clone V9 (Dako, M0725),
which has no cross-reactivity with mouse vimentin (Valadez et al.,
2014). We also determined the levels of immune cells positive for
CD3-Ɛ using a 1:10 dilution of Armenian Hamster anti-CD3-Ɛ
antibody-FITC followed by a 1:100 dilution of the secondary mouse
anti-FITC antibody (clone FL-D6, Cat# A1812, Sigma). The HiDefTM
HRP-polymer system was used for detection (Cell Marque, Rocklin,
CA). Endogenous peroxidase activity was eliminated with treatment
under mild conditions as follows: 1.8% H2O2 for 5 min, 1% periodate
for 5 min, and 0.02% NaBH4 for 2 min (Polak and Van Noorden, 2003).
Signal detection was based on the Dako DAB chromogen kit according
to the manufacturer's guidelines. We found that hot citric acid and
slow cooling of the slide/citrate solution to room temperature
(N20min) was the best method to retrieve the epitope, but lost epitope
if we cooled quickly. The complete methodology can be found in
Supplemental Experimental Procedure 1.
2.7. Chemical Synthesis of MP-MUS
A full description of the synthesis and characterization of MP-MUS
has been recently published by our laboratory (Sharpe et al., 2015).
The synthetic route taken for the synthesis of MP-MUS that was used
in our initial work is found in Supplemental Experimental Procedure
2. It should be noted that the BOP used in this synthesis generates a
carcinogenic hexamethylphosphoramide product. We advise that our
ChemMedChem route which does not use BOP, be used instead.
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Statistical analyses were performed with Microsoft Ofﬁce Excel. All
numerical data are presented as mean± SEM. An n number is a unique
experiment, typically an image or enzyme-linked assay performed in a
single well. Grouped analysis was performed by ANOVA. Pairwise
analysis was performing using the Student's t-test with p b 0.05 as the
threshold for statistical signiﬁcance following a Bonferroni correction
for multiple analyses.
3. Results
3.1. Inhibition of MAOB Attenuates MP-MUS-Induced Mitochondrial
Toxicity
Wedemonstrated thatMP-MUS targets themitochondria of primary
human glioma cells in a MAOB-dependent manner (Fig. 2). Human
glioblastoma cells were incubated with or without MP-MUS for 24 h
in the absence or presence of the MAOB-speciﬁc inhibitor selegiline
(Fig. 2A). We examined mitochondrial ΔΨ, formamidopyrimidine-
DNA glycosylase or 8-oxoguanine DNA glycosylase (fpg)-sensitive
DNA lesions, andMAOB by ﬂuorescencemicroscopy. TheMitoTracker™
ΔΨ signal per cell was not signiﬁcantly affected in cells treated with
2 μM selegiline compared to DMSO vehicle. However, 90 μMMP-MUS
resulted in a 50% reduction in ΔΨ (p b 0.0001 for n= 8 images from in-
dividual wells), which was completely blocked by co-treatment with
selegiline. The MitoTracker™ signal is a proxy for both mitochondrial
density and mitochondrial energization status. Low signal levels indi-
cate that either the mitochondria are depolarized, thus incapable of
generating signiﬁcant levels of ATP by oxidative phosphorylation, or
that the number of mitochondria per cell has dropped, or both. Oxida-
tion and alkylation of mtDNA was evaluated by the fpg-ddTUNEL
assay (Sharpe et al., 2012; Baskin et al., 2010b). MP-MUS increased
fpg-sensitive oxidation/alkylation of DNA bases by 60% (p b 0.0001).
Statistically signiﬁcant changes in mitochondrial or nuclear DNA dam-
age were not observed in cells treated with selegiline alone or with
the combination of selegiline and MP-MUS. MP-PUS treatment caused
a signiﬁcant (p b 0.001) 220% increase in MAOB antibody labeling.
Thus, MP-MUS damaged mtDNA through anMAOB-dependent mecha-
nism that was blocked by selegiline.
The effects ofMP-MUS treatment duration onΔΨ, fpg-sensitive DNA
lesions, and MAOB in glioblastoma cells are shown in Fig. 2B. After only
30 min, 20% of the ΔΨ signal was lost (p b 0.05); after two hours,
MP-MUS-treated cells had 70% of the control mitochondrial ΔΨ (p b
0.001). We observed an initial 20% increase in fpg-sensitive DNA lesions
after 30 min of treatment; these lesions continued to increase before
damaged DNA levels reached a plateau at 30% above control levels at
24 h. There was a 40% increase in MAOB levels within 30 min of
treatment and a 60% increase by one hour. MAOB levels showed a slight
decline at 2 h after treatment, which is when cells began to die and
detach. A time series is shown for three mitochondrial parameters in
Fig. 2C. All data showed statistically signiﬁcant changes beyond
30 min of treatment, with the exception of the fpg-assay at 120 min
(‡).Wedid not observe statistically signiﬁcant changes inmitochondrial
phenotype at incubation times b30 min, which may be due to MAOB-
induced maturation of the pro-drug and mtDNA replication time
(≈17 min) (Song et al., 2011).
3.2. MP-MUS is a Glioblastoma Toxin In Vitro
We examined the concentration range at which MP-MUS affected
the viability of glioma cells. Cells were cultured in a 96-well plate for
24 h. Viability was assessed by counting cells using ﬂuorescence
microscopy, measuring the levels of mitochondrial complexes I and III
using the XTT assay, and measuring the levels of detergent-
permeabilized lactate dehydrogenase. Hoechst staining showed thatthe LD50 ofMP-MUSwas 77 μMafter 24 h in primary human glioma cul-
tures (Fig. 3A), whereas the LD50 was 50 μM at 48 h (data not shown).
Total cellular LDH levels are an indicator of glucose/lactate ﬂux
(‘anaerobic respiration’) and XTT reduction levels are an indicator of
the respiratory ﬂux through the respiratory chain (‘aerobic ﬂux’),
when combined with cell numbers these assays are informative as to
changes in cellular energy changes. MP-MUS affected levels of both
XTT formazan generation and glioblastoma lactate dehydrogenase
levels (Fig. 3B) and the changes in theproxy's anaerobic and aerobic res-
piration are quite different from changes in cell counts (Fig. 3A); Treat-
ment with MP-MUS increased the levels of mitochondrial complexes
and lactate dehydrogenase in glioma cells. In Figs. 3A and B one can
compare the levels of LDH and XTT in the control and in cells treated
with 90 μMMP-MUS to be alerted to the fact that large-scale metabolic
changes occur in response toMP-MUS. There are less than half the total
number of cells that have been treated with 90 μMMP-MUS treated as
in the controls (Fig. 3A). None the less, thismuch smaller cell population
has almost the same level of LDH and XTT formazan production as the
more numerous control cells (Fig. 3B). Thus, on a per cell basis, 90 μM
MP-MUS induces a 2.2-fold increase in cellular mitochondrial levels
and a 2-fold increase in lactate dehydrogenase activity.
Parallel control experiments were performed to examine the effects
of blocking the activity of MAOB or the parental mustard compound.
MitochondrialΔΨ, XTT reduction, LDH levels, cell viability, and the per-
centage of dead cells did not change in response to co-treatment with
210 μMMP-MUS and 2 μM selegiline. Similarly, 210 μM of the parental
mustard compound, 2,2′-dichlorodiethylamine, did not signiﬁcantly
alter any of the measured parameters in glioma cells (Fig. S2). Thus,
MP-MUS toxicity toward glioblastoma cells is dependent upon its con-
version to P+-MUS, by MAOB and not due to MP-MUS itself nor the pa-
rental mustards toxicity. In Fig. 2 we showed that the MitoTracker™
signal collapses after 24 h incubation with 90 μM MP-MUS, while
Fig. 3B shows that concurrent with this loss of mitochondrial signal
there is a doubling, per cell, of the rate that XTT is reduced bymitochon-
drial complexes, which is mirrored by the increase in MAOB levels
(Fig. 2A). Thus, in response to MP-MUS glioblastoma increase their
mitochondrial levels, but these mitochondria are poorly energized and
so are less able to maintain normal ATP production.
3.3. MP-MUS Induces Changes in Reactive Oxygen Species (ROS) Levels and
Other Cellular Responses in vitro
In addition to damaging glioblastoma mtDNA, MP-MUS increased
the levels of mitochondrial ROS (Fig. 4). In addition, exposure of cells
to 90 μM MP-MUS increased mitochondrial MitoTracker™ labeling
and lactate dehydrogenase A (LDHA) levels. The levels of mitochondrial
proteins cytochrome c (columns I–II) and MAOB (columns III–IV)
(Fig. 4A, labeled in red) increased by 70% and 130% (plotted in
Fig. 4B). The increased mitochondrial levels were accompanied by a
4.8-fold increase in LDHA levels (column V, red). These changes in pro-
tein levelswere consistentwith the increasedmitochondrial respiratory
chain activity and increased LDH activity, per cell, following exposure to
MP-MUS (Fig. 3).
Four different oxidative stress assays (all depicted in green) were
also performedwith the same glioma cultures labeled formitochondrial
proteins. The levels of cellular aldehydes and ketones, including protein
carbonyls, were labeled with biotin-hydrazine and visualized with ﬂuo-
rescein isothiocyanate labeled avidin (FITC-avidin); Fig. 4A (I). No
changes in the overall levels of these markers of oxidative stress were
found in MP-MUS-treated gliomas. The levels of damaged DNA were
signiﬁcantly increased, as determined by labeling 3′-OH DNA breaks
and nicks using ddTUNEL; Fig. 4A (II). Damaged DNA was identiﬁed as
mtDNAbased on the extra-nuclear location and co-localizationwithmi-
tochondrial protein markers. Formation of 2′-7′dichloroﬂuorescein
(DCF), a measure of steady-state cellular peroxides, increased by 75%
after MP-MUS treatment and co-localized with mitochondria; Fig. 4A
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showed a three-fold increase in hydroxyl radical production, Fig. 4A
(IV), which was indicative of mitochondrial Fenton chemistry (Sharpe
et al., 2012). Histograms and statistical signiﬁcance of the changes in
labeling due to incubation with MP-MUS are shown in Fig. 4B. We
examined control- and MP-MUS-treated cells at high resolution with
MAOB labeled in red, 3′OH DNA nicks/breaks labeled in green, and
DAPI labeled in blue (Fig. 4C). DNA damage was only visible in the
cytosol, indicating that mtDNA, rather than nuclear DNA, was the target
of MP-MUS.
These data (Figs. 2–4) demonstrate thatMP-MUS is highly damaging
to mitochondria in glioblastoma cultures. In response to this damage
the glioblastoma cells respond by increasing mitochondrial biogenesis
and upregulate production of LDHA.3.4. MP-MUS Decreases Tumor Volume in a Flank Model of GBM But Does
Not Cause Parkinsonian Syndromes
We examined the effects of two MP-MUS treatment regimens on
primary human glioma xenografts in a Nu/Nu nude mouse model
(Fig. 5). Saline or 0.2 mg MP-MUS in saline was injected into the tail
veins of mice (≈25 g), 8 mg/kg, on days 0, 12, and 23 with seven
mice per group (Fig. 5A). None of themice exhibited adverse symptoms
or weight loss during the study period. Tumor volumes shrank in the
MP-MUS treatment group after the ﬁrst injection, whereas tumors in
the saline controls grew steadily throughout the study. Tumor volumes
were signiﬁcantly different between groups (p b 0.0005) from day
22 onward.Fig. 5.MP-MUS is a chemotherapeutic in aﬂank glioblastomamodel. (A) Three treatments
of 8 mg/kg of MP-MUS were able to halt tumor growth compared with saline controls.
(B) A single treatment of 8 mg/kg MP-MUS was able to shrink tumor volume by 50% in
24 h.The two control mice with the largest tumors and all seven mice
treated with MP-MUS were sacriﬁced on day 36. No tumors were de-
tected in two of the seven MP-MUS-treated mice. Half of the excised
tumor tissue was used for histological studies, and the remaining
portion was gently homogenized and grown in culture. In addition,
the major organs were ﬁxed, sectioned, and examined by H&E staining
and ddTUNEL for identiﬁcation of apoptotic nuclei. No abnormalities or
differences were found in the major organs of control or treated
animals. Necrotic areas and increased numbers of apoptotic, ddTUNEL-
positive cells were found in MP-MUS-treated xenografts compared
with those of controls. Representative images of ddTUNEL and DAPI
labeled saline control and MP-MUS treated tumors are shown in
Supplemental Fig. 3. Cells undergoing apoptotic cell death were present
in both tumor types, but are more numerous in the MP-MUS treated
tissue. In addition, ddTUNEL labeling is found in many non-apoptotic
MP-MUS treated cells, with DNA damage localized within the cytosol,
suggesting that these cells have mtDNA damage.
The ﬁve remaining saline-treated control mice were given a single
injection of 0.2 mgMP-MUS. A greater than 50% decrease in tumor bur-
den occurred after 24 h of treatment (Fig. 5B). Thus, a single treatment
withMP-MUSwas effective against large,well-established glioblastoma
tumors.
Treatment of mice with MPTP gives rise to a phenotype indicating
dysfunctional motor control resembling those in human Parkinson's
disease, and symptoms include akinesia, rigidity, tremor, gait and
posture disturbances (Sedelis et al., 2001). In preliminary toxicology
studies, and in the following efﬁcacy studies, we observed no evidence
of symptoms consistent with the induction of Parkinsonian syndromes.
To investigate whether MP-MUS usage had caused ablation of dopami-
nergic neurons, but at a level that was behaviorally asymptomatic, we
performed a number of histological studies on the brains of mice used
in preliminary toxicology studies. We probed saline control and
MP-MUS treated brains for dopaminergic neuronal density, using a ty-
rosine hydroxylase speciﬁc monoclonal antibody and typical low and
high magniﬁed images are shown in Supplemental Fig. 4. We found
no indication of loss of dopaminergic neurons in any of the MP-MUS
treated mouse brain sections in this study. Treatment of mice with
MPTP can also give rise to inﬁltration of surviving dopaminergic neu-
rons by activated astrocytes (Ghosh et al., 2012) and to iron rich voids
that are formed following dopaminergic neuronal cell death (Jiang
et al., 2010). We labeled the brain slices of the same two cohorts for
iron, using Perl's Prussian blue, and for astrocytic inﬁltrates, using
anti-GFAP antibodies, and could not identify any differences between
the MP-MUS treated and untreated groups (results not shown).
3.5. MP-MUS Treatment of Xenografts Induces Changes in the Glioblastoma
Phenotype
We then examined if permanent changes to the mitochondrial phe-
notypewere present in theMP-MUS-treated glioblastoma tumors. Cells
grown from MP-MUS-treated or saline-treated xenografts were
assessed for markers of mitochondrial function and oxidative stress.
The levels of Mitotracker™ andMitoSox, whichmeasure mitochondrial
superoxide, were statistically identical between the two treatment
groups. However, cells from the MP-MUS xenografts exhibited a 2.8-
fold increase in the level of mitochondrial MAOB and 1.9-fold increase
in the level of cytosolic 3′OH mtDNA nicks and breaks (Figs. 6A and
6B).We explored the type ofmtDNAdamage usingblunt-ended ligation
as previously described (Baskin et al., 2010a).MP-MUS-treated glioblas-
toma xenografts had ~50% more blunt-ended mtDNA breaks (Fig. 6C).
These mitochondria increased cellular oxidative stress because there
was a 50% greater level of hydroxyl radical generation and a 3.5-fold
increase in the steady state levels of peroxides in cells derived from
MP-MUS-treated xenografts. MP-MUS treatment affects the glioblasto-
ma phenotype, with subsequent daughter cells having altered
mitochondrial function, presumably due to heritable mtDNA damage.
Fig. 6. Alteration in glioblastoma phenotype after MP-MUS treatment. (A) Representative images of the two cell lineages treated ± MP-MUS show an increase in steady state of MAOB
levels, mtDNA lesions and permanent changes in the generation of reactive oxygen species. (B) Graphical representations of the altered phenotypes are shown with signiﬁcant changes
in levels ofMAOB, themtDNA breaks, peroxides and hydroxyl radical. ** p b 0.01 and *** p b 0.005 at the n=number of individualwells shown in the insert. (C) High resolution images of
blunt ended DNA breaks (green) and DNA (blue) of cells grown from xenografts. Blunt-ended DNA is non-nuclear, cytosolic mtDNA with some invaginations of cytosol into the nucleus.
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To study the effects of MP-MUS on morbidity and body mass, we
used an intracranial mouse model of primary human GBM (Fig. 7A
and 7B). NOD/SCID mice were randomized into two treatment groups
(n = 11 mice per group). Primary human GBM cells encased in a
Matrigel matrix were injected into the right hemisphere of the brain
of each mouse using the method developed by Iwami and co-workers
(Iwami et al., 2012). The ﬁrst of three tail-vein injections of saline
or 0.2 mg MP-MUS, 8 mg/kg, was delivered on day 115. The saline-
treated group exhibitedmorbidity in 50% of animals on day 248,where-
as theMP-MUS treatment group had only one symptomaticmouse dur-
ing the entire experimental period. Shortly after the ﬁnal injection,
animals in the MP-MUS-treated group steadily gained weight. In con-
trast, control mice showed a delayed weight gain after the ﬁnal saline
injection. Saline controls initially averaged 95% of the weight of MP-
MUS-treated animals; however, the bodyweights of control animals de-
clined consistently after day 250 until weights were about 88% of the
ﬁnal average weight of the MP-MUS-treated mice. In addition to a fail-
ure to thrive,most of the control mice lost clumps of body hair through-
out the study, typically prior to the onset of neurological deﬁcits or
sudden weight loss; in contrast, only 40% of the MP-MUS-treated
group exhibited these changes. Fig. S5 shows the surviving control
mice on day 307 compared with four representative MP-MUS treated
animals.
After the onset of symptoms that indicated an ethical endpoint or at
the end of the study, we performed a sagittal brain dissection into two
hemispheres and prepared sections for microscopy. We identiﬁed inﬁl-
trating human cells with a mouse anti-vimentin antibody derived from
V9, a clone that does not bind to mouse vimentin (Caretti et al., 2011).This antibody recognizes all non-mouse forms of vimentin in a mouse
vimentin background. We also used an antibody against CD3-Ɛ to
label another set of hemispheric pairings. CD3-Ɛ is found on the surface
of tumor-associated macrophages and T-cells (Borroto et al., 2014) and
serves as an indicator of increased immune response to glioma xeno-
grafts in rodents (Kong et al., 2012; Strojnik et al., 2010).
DAB-stained images of human vimentin (I), a no-primary internal
control (II), and CD3-Ɛ staining (III) of sequential slices of the left hemi-
sphere of a saline control brain, all mounted on a single slide, are shown
on in Fig. 7C. The same vimentin-labeled section of individual human
glioblastoma cells in the right hemisphere inﬁltrating the left hemi-
sphere is also shown at an increasedmagniﬁcation [Fig. 7D (I)]. To con-
ﬁrm that we had labeled human cells and were not observing artifacts,
we also labeled DNAwith DAPI.We took an image of the DAB-vimentin
cells using transmitted black andwhite light [Fig. 7E (I)] and an image of
DAPI ﬂuorescence (II). The overlaid image [Fig. 7E (III)] shows that nu-
clear DNA co-localized with DAB staining and that DAB staining attenu-
ates DAPI ﬂuorescence. The DAPI signal was inside DAB-labeled cells,
indicating that the antibodies were recognizing the correct cellular
antigen.
3.7. MP-MUS Treatment Lowers Glioma Burden in Intracranial Xenografts
Glioma xenografts were developed in the right hemisphere of the
brain of eachmouse; thus, a comparison of right & left hemisphere glio-
blastoma load is an index of glioblastoma inﬁltration. The glioblastoma
load and levels of CD3-Ɛ-positive cells in each hemisphere of all 22 an-
imals are shown in Supplementary Table 1.We found human gliomas in
100% of the right hemispheres of the brains of control mice, with inﬁl-
tration into the left hemispheres of 10 of 11 control mice. In contrast,
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treated with MP-MUS. There were glioblastoma cells in the right hemi-
spheres of 6 of 11 MP-MUS-treated mice, but there were no glioblasto-
ma inﬁltrates into the left hemispheres. The only symptomatic MP-
MUS-treated animal that reached an ethical endpoint (MP-MUS #1)
had a very low glioblastoma burden; positive cells were observed in
only one 5-μM section on one slide of a sample near the injection
point (Fig. 7F). Although we observed very few human glioma cells,
we found large numbers of activated immune cells positive for CD3-Ɛ.
The highest glioblastoma burden in an MP-MUS-treated mouse
(MP-MUS #8) occurred near the injection site and glioblastoma cells
co-localized with CD3-Ɛ-positive cells, Fig. 7F. CD3-Ɛ-positive cells
were located in both brain hemispheres of all saline-treated controls.
CD3-Ɛ-positive cells were found in the injected and uninjected hemi-
spheres of 7 of 11MP-MUS-treated animals.Wewere unable to identify
any CD3-Ɛ-positive immune cells or gliomas in the remaining four
MP-MUS-treated mouse brains.4. Discussion
Human gliomas exhibit signiﬁcant and selective increases in MAOB
activity compared to other types of common brain tumors, such as me-
ningiomas (Callado et al., 2011), or non-tumor-bearing brain tissues
(Gabilondo et al., 2008). This characteristic presents a distinct opportu-
nity for rational drug design using MAOB as a catalyst for converting a
non-toxic pro-drug into a mature chemotherapeutic, as demonstrated
here with MP-MUS. The ability of MAO to irreversibly oxidize the neu-
tral 1,2,3,6-tetrahydropyridine into a cationic pyridinium species is the
basis of the mitochondria-mediated neurotoxicity of MPTP (Visanji
and Brotchie, 2001; Shi et al., 1999; Sullivan and Tipton, 1990); this
mechanism was the starting point for our pro-drug design. An ideal
MAOB-activated pro-drug should cross the blood–brain barrier and
have high MAOB ﬂux and high speciﬁcity for MAOB versus MAO-A.
The design of the “warhead” attached to the tetrahydropyridine
“seeker”, N,N‐bis(2‐chloroethyl) propanamide, was partly based on
the size, shape, and LogP of the indolyl and 4-(1-methylpyrrol-2-yl) an-
alogues of MPTP, which have very good MAOB kinetic properties
(Sullivan and Tipton, 1990; Nimkar et al., 1996, 1999).
Sub-lethal levels of MP-MUS induce increased levels of mitochon-
dria and mitochondrial MAOB in glioma cells in vitro and in vivo. Cells
derived from MP-MUS-treated glioma xenografts harbored dysfunc-
tional mitochondria many generations after treatment. The mitochon-
dria in these cells had increased MAOB expression and increased ROS
generation. Thus, glioma cells that survive after one or more cycles of
MP-MUS treatment express increased levels of MAOB, rendering these
glioma cells more sensitive to MP-MUS therapy. Unlike most chemo-
therapeutic drugs, which lose their efﬁcacy during repetitive rechal-
lenge, giving rise to drug resistance, serial challenge with MP-MUS
appears to have the opposite effect; MP-MUS treated cells upregulate
mitochondrial levels, and in doing so further upregulate their levels of
MAOB, making them sensitive to further MP-MUS treatment.
We have recently shown the kinetics of rhMAO-A/-B acting on
MP-MUS and known MAO substrates (Sharpe et al., 2015). MP-MUS is
a very poor rhMAO-A substrate, but MP-MUS has a similar km and
Vmax to benzylamine in rhMAOB. We also show that in vitro, MP-MUS
is more toxic to primary GBM than to normal human astrocytes and
that this difference in toxicity at least partly due to the higher levels of
MAOB in glioma.Fig. 7. Glioblastoma successfully treated by MP-MUS in an intracranial xenograft model.(A) K
(8 mg/kg) tail vein injections, n= 11.(B) Alteration in mouse body mass during course
treated.(C) Labeling of uninjected hemisphere of saline treated mouse with (I) anti-vimentin
IgG control (background peroxidase activity).(D) Images of C. (I) taken as increasing ma
cells.(E) Unambiguous demonstration that vimentin labeling co-localized with DAPI/nuc
staining.(F) Levels of glioma and CD3-ε in MP-MUS treated brain (right hemispheres).MP-MU
beling is found throughout hemisphere.MP-MUS #8 has the most vimentin signal, hence gliobIt is possible that likeMPP+, P+-MUS could be a dopamine transport-
er substrate and so can induce Parkinsonian syndromes due to
DAT-mediated toxicity. We designed MP-MUS so that the active com-
pound, P+-MUS, would be too large to serve as a DAT substrate, based
on the known kinetics of MPP+ analogues. We observed no Parkinsonian
symptoms in any of theMP-MUS treated animals, nor did an examination
of treated brains reveal any toxicity toward the dopaminergic neurons. As
human and mouse DAT share very similar sequence homology and
substrate kinetics (Han and Gu, 2006) the inability of MP-MUS to target
mouse dopaminergic neurons via DAT-mediated toxicity should be repli-
cated in humans.
Treatment of glioblastoma has been a challenge for decades. The Ra-
diation Therapy Oncology Group (RTOG) study in 1993 demonstrated
the limited value of surgery (Simpson et al., 1993). Patients who
underwent radical surgery and radiotherapy vs. biopsy only and radia-
tion therapy had an increase in survival from only 6.6 to 11.3 months.
The addition of radiation therapy and chemotherapy, including the
use of temozolomide, has only extended median survival to 15 months
over 20 years later. Furthermore, the ﬁnal 3 months of life generally
have a low quality attached to them. Thus, a novel approach is desper-
ately needed for these patients.
MP-MUSmaybe such a therapy. It targets an essential organelle of the
cell, the mitochondria, which cancer cells must have to survive. The up
regulation of MAOB in response to treatment is a maladaptive response
of the glioma cell, which may work to the advantage of treatment.
The next steps for this construct is to perform detailed toxicological
studies, pharmacodynamic testing, and to ﬁne-tune the details of the
manufacturing process. This work is under way, and we are hopeful to
see this drug in clinical trials in the next 18 months.Author Contributions
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